Abstract
Portal hypertension is a hemodynamic abnormality that involves a high risk of disability as well as a reduced life expectancy in patients with cirrhosis. Progress in the knowledge of pathophysiology of portal hypertension has opened a new perspective for different pharmacological approaches. In this context, the pleiotropic actions of statins on endothelial cell function have emerged as new options to reduce portal pressure levels by targeting multiple molecular pathways involved in hepatic vascular homeostasis. We highlight how statins may target some molecular pathways involved in the pathophysiology of portal hypertension and how these drugs may correct impaired hepatic vascular tone.
Keywords: Liver cirrhosis, statins, portal hypertension, hepatic stellate cell, intrahepatic vascular resistance, vascular endothelium
Current Vascular Pharmacology
Title:Statins and Portal Hypertension: A New Pharmacological Challenge
Volume: 10 Issue: 6
Author(s): Gonzalo Ramirez, Jimmy Briceno and Armando Rojas
Affiliation:
Keywords: Liver cirrhosis, statins, portal hypertension, hepatic stellate cell, intrahepatic vascular resistance, vascular endothelium
Abstract: Portal hypertension is a hemodynamic abnormality that involves a high risk of disability as well as a reduced life expectancy in patients with cirrhosis. Progress in the knowledge of pathophysiology of portal hypertension has opened a new perspective for different pharmacological approaches. In this context, the pleiotropic actions of statins on endothelial cell function have emerged as new options to reduce portal pressure levels by targeting multiple molecular pathways involved in hepatic vascular homeostasis. We highlight how statins may target some molecular pathways involved in the pathophysiology of portal hypertension and how these drugs may correct impaired hepatic vascular tone.
Export Options
About this article
Cite this article as:
Ramirez Gonzalo, Briceno Jimmy and Rojas Armando, Statins and Portal Hypertension: A New Pharmacological Challenge, Current Vascular Pharmacology 2012; 10 (6) . https://dx.doi.org/10.2174/157016112803520918
DOI https://dx.doi.org/10.2174/157016112803520918 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gene Expression Suggests Spontaneously Hypertensive Rats May Have Altered Metabolism and Reduced Hypoxic Tolerance
Current Neurovascular Research Midlife Modifiable Risk Factors for Dementia: A Systematic Review and Meta-analysis of 34 Prospective Cohort Studies
Current Alzheimer Research Centrality Measures in Biological Networks
Current Bioinformatics Editorial (Thematic Issue: Novel Agents in the Treatment of Osteoporosis and Its Complications)
Current Drug Targets Role of ERK1/2 Activation In Thrombin-Induced Vascular Smooth Muscle Cell Hypertrophy
Current Hypertension Reviews Stage B: What is the Evidence for Treatment of Asymptomatic Left Ventricular Dysfunction?
Current Cardiology Reviews Vascular Remodelling in Well-controlled Hypertensive Patients: The Challenge of Residual Risk Management
Current Pharmaceutical Design The Economics of Pharmacogenomics
Current Pharmacogenomics Therapeutic Potential of Neuregulin in Cardiovascular System: Can we Ignore the Effects of Neuregulin on Electrophysiology?
Mini-Reviews in Medicinal Chemistry The Role of Intravenous Dihydropyridine Calcium Channel Blockers in the Perioperative Management of Patients Undergoing Coronary Artery Bypass Surgery
Current Vascular Pharmacology Impact of Computational Structure-based Methods on Drug Discovery
Current Pharmaceutical Design Polyunsaturated Fatty Acids in Pregnancy and Metabolic Syndrome: A Review
Current Pharmaceutical Biotechnology Caffeine as a Lead Compound for the Design of Therapeutic Agents for the Treatment of Parkinson’s Disease
Current Medicinal Chemistry Targeting the Role of Lipoprotein (a) in Stroke
Cardiovascular & Hematological Disorders-Drug Targets Design, Synthesis, and Bioactivity of Pyrazole Acid Derivatives as Endothelin Receptor Antagonists
Medicinal Chemistry Successful Applications of Computer Aided Drug Discovery: Moving Drugs from Concept to the Clinic
Current Topics in Medicinal Chemistry Potential Options to Treat Hypertriglyceridaemia
Current Drug Targets Heart Failure
Current Hypertension Reviews Type 1 11 β-hydroxysteroid Dehydrogenase as Universal Drug Target in Metabolic Diseases?
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Drugs of Abuse: A Snapshot of an Evolving Marketplace
Adolescent Psychiatry